Bulevirtide
Hepcludex (bulevirtide) is a protein pharmaceutical. Bulevirtide was first approved as Hepcludex on 2020-07-31. It has been approved in Europe to treat chronic hepatitis d.
| Trade Name | Hepcludex |
|---|---|
| Common Name | Bulevirtide |
| Indication | chronic hepatitis d |
| Drug Class | Peptides: antiviral peptides; antivirals |
